EcoDrugPlus

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSLOCG00000014528
Gene Symbol: GRIA3
3 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSLOCG00000006993
Gene Symbol: GRIA4
3 Cross references
324 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSLOCG00000000420
Gene Symbol: GRIN1
3 Cross references
279 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSLOCG00000006209
Gene Symbol: GRIN2A
3 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSLOCG00000011140
Gene Symbol: GRIN2C
3 Cross references
249 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSLOCG00000002735
Gene Symbol: GRIN3A
4 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSLOCG00000001847
Gene Symbol: GRIN3B
3 Cross references
286 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSLOCG00000009083
Gene Symbol: GRIK1
3 Cross references
313 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSLOCG00000016542
Gene Symbol: GRIK2
4 Cross references
334 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSLOCG00000003209
Gene Symbol: GRIK3
4 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSLOCG00000002001
Gene Symbol: GRIK4
3 Cross references
260 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSLOCG00000016703
Gene Symbol: GRM3
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).